Kevin McLaughlin Net Worth

The estimated Net Worth of Kevin F Mclaughlin is at least $12.8 Milhão dollars as of 7 August 2024. Mr. Mclaughlin owns over 7,000 units of Acceleron Pharma Inc stock worth over $2,484,625 and over the last 11 years he sold XLRN stock worth over $8,856,192. In addition, he makes $1,460,530 as Chief Financial Officer, Senior Vice President, e Treasurer at Acceleron Pharma Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Mr. McLaughlin XLRN stock SEC Form 4 insiders trading

Kevin has made over 55 trades of the Acceleron Pharma Inc stock since 2014, according to the Form 4 filled with the SEC. Most recently he exercised 7,000 units of XLRN stock worth $26,180 on 7 August 2024.

The largest trade he's ever made was exercising 54,000 units of Acceleron Pharma Inc stock on 8 April 2020 worth over $1,913,760. On average, Kevin trades about 8,800 units every 53 days since 2013. As of 7 August 2024 he still owns at least 13,900 units of Acceleron Pharma Inc stock.

You can see the complete history of Mr. Mclaughlin stock trades at the bottom of the page.

Kevin McLaughlin biography

Kevin F. McLaughlin serves as Chief Financial Officer, Senior Vice President, Treasurer of the Company. Mr. McLaughlin joined Acceleron in November 2010 and is our Senior Vice President, Chief Financial Officer and Treasurer. Mr. McLaughlin has served on the board of directors of Vericel Corporation since January 2015 and on the board of directors of Stealth Biotherapeutics Inc. since August 2017. He also previously served, from 2009 through 2010, as Senior Vice President and Chief Financial Officer of Qteros, Inc. He was a co-founder of Aptius Education, Inc. and from 2007 through 2009 he worked as the Chief Operating Officer and a director. From 1996 through 2007, Mr. McLaughlin held several executive positions with PRAECIS Pharmaceuticals, Inc. He joined PRAECIS as their first Chief Financial Officer where he had responsibility for private financings, partnership financings, the company's initial public offering and subsequent stock offering. Later, Mr. McLaughlin became COO, and then President and CEO, and he served as a member of the board of directors. In this capacity he was responsible for negotiating the sale of the company to GlaxoSmithKline. He began his career in senior financial roles at Prime Computer and Computervision Corporation. Mr. McLaughlin received a B.S. in business from Northeastern University and an MBA from Babson College.

What is the salary of Kevin McLaughlin?

As the Chief Financial Officer, Senior Vice President, e Treasurer of Acceleron Pharma Inc, the total compensation of Kevin McLaughlin at Acceleron Pharma Inc is $1,460,530. There are 1 executives at Acceleron Pharma Inc getting paid more, with Habib Dable having the highest compensation of $4,273,090.

How old is Kevin McLaughlin?

Kevin McLaughlin is 63, he's been the Chief Financial Officer, Senior Vice President, e Treasurer of Acceleron Pharma Inc since 2010. There are 3 older and 8 younger executives at Acceleron Pharma Inc. The oldest executive at Acceleron Pharma Inc is Jay Backstrom, 65, who is the Executive Vice President - Research and Development.

What's Kevin McLaughlin's mailing address?

Kevin's mailing address filed with the SEC is C/O VERICEL CORPORATION, 64 SIDNEY STREET, CAMBRIDGE, MA, 02139.

Insiders trading at Acceleron Pharma Inc

Over the last 11 years, insiders at Acceleron Pharma Inc have traded over $211,038,855 worth of Acceleron Pharma Inc stock and bought 4,435,573 units worth $172,392,007 . The most active insiders traders include Corp /De/ Celgene, Richard F Pops, eAnthony B Evnin. On average, Acceleron Pharma Inc executives and independent directors trade stock every 10 days with the average trade being worth of $7,646,210. The most recent stock trade was executed by Adam M Veness on 9 November 2021, trading 4,500 units of XLRN stock currently worth $132,165.

What does Acceleron Pharma Inc do?

Acceleron is a biopharmaceutical company dedicated to the discovery, development, and commercialization of therapeutics to treat serious and rare diseases. Acceleron's leadership in the understanding of TGF-beta superfamily biology and protein engineering generates innovative compounds that engage the body's ability to regulate cellular growth and repair.

Complete history of Mr. Mclaughlin stock trades at Acceleron Pharma Inc e Vericel Corp

Acceleron Pharma Inc executives and stock owners

Acceleron Pharma Inc executives and other stock owners filed with the SEC include:

• Habib Dable,
  President, Chief Executive Officer, Director
• Kevin McLaughlin,
  Chief Financial Officer, Senior Vice President, Treasurer
• Sujay Kango,
  Executive Vice President and Chief Commercial Officer
• Ravindra Kumar,
  Senior Vice President, Chief Scientific Officer
• Francois Nader,
  Independent Chairman of the Board
• Joseph Zakrzewski,
  Independent Director
• Terrence Kearney,
  Independent Director
• Thomas McCourt,
  Independent Director
• Karen Smith,
  Independent Director
• Todd James,
  Senior Vice President Corporate Affairs and Investor Relations
• Kemal Malik,
  Independent Director
• Christopher Hite,
  Director
• Laura Hamill,
  Director
• Jay Backstrom,
  Executive Vice President - Research and Development
• Terrance Mcguire,
  Director
• Tom Maniatis,
  Director
• Jean George,
  Director
• John L Knopf,
  CEO and President
• Steven D Ertel,
  SVP & Chief Business Officer
• Matthew L Sherman,
  SVP & Chief Medical Officer
• Richard F Pops,
  Director
• Adam M Veness,
  SVP, General Counsel and Sec.
• John D Quisel,
  EVP, Chief Business Officer
• Christopher Rovaldi,
  SVP, Program Mgmt and Ops
• Robert K Zeldin,
  EVP & Chief Medical Officer
• Corp /De/ Celgene,
  10% owner
• Anthony B Evnin,
  Director
• Edwin M Jr Kania,
  Director
• Venture Management Co Iv Ll...,
  
• Venture Management Co Iv Ll...,
  
• Advisors Llcorbimed Capital...,
  
• Corp /De/Bristol Myers Squi...,